Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial. (6th November 2014)

Record Type:: Journal Article
Title:: Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial. (6th November 2014)
Main Title:: Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
Authors:: Kaufman, Howard L
Andtbacka, Robert HI
Collichio, Frances A
Wolf, Michael
Li, Ai
Shilkrut, Mark
Puzanov, Igor
Ross, Merrick
Abstract:
Is Part Of:: Journal for immunotherapy of cancer. Volume 2(2014)Supplement 3
Journal:: Journal for immunotherapy of cancer
Issue:: Volume 2(2014)Supplement 3
Issue Display:: Volume 2, Issue 3 (2014)
Year:: 2014
Volume:: 2
Issue:: 3
Issue Sort Value:: 2014-0002-0003-0000
Page Start:
Page End:
Publication Date:: 2014-11-06
Subjects:: Overall Survival -- Median Overall Survival -- Durable Response -- Antitumor Immune Response -- OPTiM Trial
Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105
Journal URLs:: http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗
DOI:: 10.1186/2051-1426-2-S3-P91 ↗
Languages:: English
ISSNs:: 2051-1426
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 19212.xml